156 related articles for article (PubMed ID: 31362685)
1. Carnosine and Kidney Diseases: What We Currently Know?
Kilis-Pstrusinska K
Curr Med Chem; 2020; 27(11):1764-1781. PubMed ID: 31362685
[TBL] [Abstract][Full Text] [Related]
2. [Carnosine, carnosinase and kidney diseases].
Kiliś-Pstrusińska K
Postepy Hig Med Dosw (Online); 2012 Apr; 66():215-21. PubMed ID: 22706107
[TBL] [Abstract][Full Text] [Related]
3. Carnosine and Diabetic Nephropathy.
Peters V; Yard B; Schmitt CP
Curr Med Chem; 2020; 27(11):1801-1812. PubMed ID: 30914013
[TBL] [Abstract][Full Text] [Related]
4. A Global Cndp1-Knock-Out Selectively Increases Renal Carnosine and Anserine Concentrations in an Age- and Gender-Specific Manner in Mice.
Weigand T; Colbatzky F; Pfeffer T; Garbade SF; Klingbeil K; Colbatzky F; Becker M; Zemva J; Bulkescher R; Schürfeld R; Thiel C; Volk N; Reuss D; Hoffmann GF; Freichel M; Hecker M; Poth T; Fleming T; Poschet G; Schmitt CP; Peters V
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664451
[TBL] [Abstract][Full Text] [Related]
5. Low plasma carnosinase activity promotes carnosinemia after carnosine ingestion in humans.
Everaert I; Taes Y; De Heer E; Baelde H; Zutinic A; Yard B; Sauerhöfer S; Vanhee L; Delanghe J; Aldini G; Derave W
Am J Physiol Renal Physiol; 2012 Jun; 302(12):F1537-44. PubMed ID: 22496410
[TBL] [Abstract][Full Text] [Related]
6. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1.
Janssen B; Hohenadel D; Brinkkoetter P; Peters V; Rind N; Fischer C; Rychlik I; Cerna M; Romzova M; de Heer E; Baelde H; Bakker SJ; Zirie M; Rondeau E; Mathieson P; Saleem MA; Meyer J; Köppel H; Sauerhoefer S; Bartram CR; Nawroth P; Hammes HP; Yard BA; Zschocke J; van der Woude FJ
Diabetes; 2005 Aug; 54(8):2320-7. PubMed ID: 16046297
[TBL] [Abstract][Full Text] [Related]
7. A CTG polymorphism in the CNDP1 gene determines the secretion of serum carnosinase in Cos-7 transfected cells.
Riedl E; Koeppel H; Brinkkoetter P; Sternik P; Steinbeisser H; Sauerhoefer S; Janssen B; van der Woude FJ; Yard BA
Diabetes; 2007 Sep; 56(9):2410-3. PubMed ID: 17601991
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic carnosine metabolism in the human kidney.
Peters V; Klessens CQ; Baelde HJ; Singler B; Veraar KA; Zutinic A; Drozak J; Zschocke J; Schmitt CP; de Heer E
Amino Acids; 2015 Dec; 47(12):2541-50. PubMed ID: 26206726
[TBL] [Abstract][Full Text] [Related]
9. Anserine inhibits carnosine degradation but in human serum carnosinase (CN1) is not correlated with histidine dipeptide concentration.
Peters V; Jansen EE; Jakobs C; Riedl E; Janssen B; Yard BA; Wedel J; Hoffmann GF; Zschocke J; Gotthardt D; Fischer C; Köppel H
Clin Chim Acta; 2011 Jan; 412(3-4):263-7. PubMed ID: 20971102
[TBL] [Abstract][Full Text] [Related]
10. Carnosinase, diabetes mellitus and the potential relevance of carnosinase deficiency.
Peters V; Zschocke J; Schmitt CP
J Inherit Metab Dis; 2018 Jan; 41(1):39-47. PubMed ID: 29027595
[TBL] [Abstract][Full Text] [Related]
11. Renoprotective effects of l-carnosine on ischemia/reperfusion-induced renal injury in rats.
Kurata H; Fujii T; Tsutsui H; Katayama T; Ohkita M; Takaoka M; Tsuruoka N; Kiso Y; Ohno Y; Fujisawa Y; Shokoji T; Nishiyama A; Abe Y; Matsumura Y
J Pharmacol Exp Ther; 2006 Nov; 319(2):640-7. PubMed ID: 16916994
[TBL] [Abstract][Full Text] [Related]
12. Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes.
Ahluwalia TS; Lindholm E; Groop LC
Diabetologia; 2011 Sep; 54(9):2295-302. PubMed ID: 21573905
[TBL] [Abstract][Full Text] [Related]
13. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
Babizhayev MA; Kasus-Jacobi A
Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
[TBL] [Abstract][Full Text] [Related]
14. CNDP1 knockout in zebrafish alters the amino acid metabolism, restrains weight gain, but does not protect from diabetic complications.
Schmöhl F; Peters V; Schmitt CP; Poschet G; Büttner M; Li X; Weigand T; Poth T; Volk N; Morgenstern J; Fleming T; Nawroth PP; Kroll J
Cell Mol Life Sci; 2019 Nov; 76(22):4551-4568. PubMed ID: 31073745
[TBL] [Abstract][Full Text] [Related]
15. Association of CTG repeat polymorphism in carnosine dipeptidase 1 (
Yadav AK; Sinha N; Kumar V; Bhansali A; Dutta P; Jha V
Indian J Med Res; 2016 Jul; 144(1):32-37. PubMed ID: 27834323
[TBL] [Abstract][Full Text] [Related]
16. FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice.
Iacobini C; Menini S; Blasetti Fantauzzi C; Pesce CM; Giaccari A; Salomone E; Lapolla A; Orioli M; Aldini G; Pugliese G
Br J Pharmacol; 2018 Jan; 175(1):53-66. PubMed ID: 29053168
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic and immunological evidence for two forms of carnosinase in the mouse.
Margolis FL; Grillo M; Brown CE; Williams TH; Pitcher RG; Elgar GJ
Biochim Biophys Acta; 1979 Oct; 570(2):311-23. PubMed ID: 497229
[TBL] [Abstract][Full Text] [Related]
18. L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes.
Menini S; Iacobini C; Fantauzzi CB; Pugliese G
Curr Med Chem; 2020; 27(11):1744-1763. PubMed ID: 31296153
[TBL] [Abstract][Full Text] [Related]
19.
Pfeffer T; Wetzel C; Kirschner P; Bartosova M; Poth T; Schwab C; Poschet G; Zemva J; Bulkescher R; Damgov I; Thiel C; Garbade SF; Klingbeil K; Peters V; Schmitt CP
Antioxidants (Basel); 2023 Jun; 12(6):. PubMed ID: 37372000
[TBL] [Abstract][Full Text] [Related]
20. Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice.
Peters V; Schmitt CP; Zschocke J; Gross ML; Brismar K; Forsberg E
Amino Acids; 2012 Jun; 42(6):2411-6. PubMed ID: 21833769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
